Decoy Therapeutics Inc. (DCOY)Healthcare | Biotechnology | Houston, United States | NasdaqCM
1.17 USD
-0.07
(-5.645%) ⇩
(Oct. 14, 2026, 4 p.m.
EDT)
|
Hot Take ↕ | Oct. 10, 2026, 1:58 a.m. EDT
The immediate outlook is severely compromised by a relentless downward trend. Over the last fourteen trading days, the price has collapsed from $3.10 to $1.47, a drop of nearly 53%, indicating intense selling pressure and a breakdown of any recent support. This crash is the final act in a nine-year saga of destruction; the asset has lost virtually all its value since inception, with four consecutive years of negative returns ending recently. The fundamental picture confirms this terminal decline: the company is burning through cash with massive operating losses, negative equity, and no revenue generation. While analysts have issued a 'strong buy' rating with a target price of $3.00, this appears to be a theoretical exercise disconnected from the harsh reality of a biotech firm with no earnings, a shrinking market cap, and a history of eroding shareholder capital. With no dividend to provide any income floor and a balance sheet that cannot sustain operations without further dilution, the investment case is non-existent. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.091791 |
| MSTL | 0.260422 |
| AutoARIMA | 0.270313 |
| AutoETS | 0.272627 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 30% |
| H-stat | 8.60 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.077 |
| Excess Kurtosis | 1.65 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Revenue per Share | 0.636 |
| Market Cap | 2,790,779 |
| Trailing P/E | 0.10 |
| Forward P/E | -0.14 |
| Beta | 0.64 |
| Previous Name | Salarius Pharmaceuticals, Inc. |
| Website | https://decoytx.com |
| Attribute | Value |
|---|---|
| 52 Week Change | -0.97568625 |
| Address1 | 2,450 Holcombe Blvd |
| Address2 | Suite X |
| All Time High | 22,338,000.0 |
| All Time Low | 1.15 |
| Ask | 2.08 |
| Ask Size | 2 |
| Average Analyst Rating | 1.0 - Strong Buy |
| Average Daily Volume10 Day | 136,350 |
| Average Daily Volume3 Month | 2,206,060 |
| Average Volume | 2,206,060 |
| Average Volume10Days | 136,350 |
| Beta | 0.644 |
| Bid | 1.3 |
| Bid Size | 2 |
| Book Value | 8.122 |
| City | Houston |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 1.17 |
| Current Ratio | 1.832 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,790,726,400 |
| Day High | 1.27 |
| Day Low | 1.1535 |
| Display Name | Decoy Therapeutics |
| Dividend Yield | 0.0 |
| Ebitda | -6,074,362 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | 1.238 |
| Enterprise To Revenue | -33.047 |
| Enterprise Value | -7,522,541 |
| Eps Current Year | -8.96 |
| Eps Forward | -8.28 |
| Eps Trailing Twelve Months | 11.55 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 15 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 2.8523 |
| Fifty Day Average Change | -1.6823 |
| Fifty Day Average Change Percent | -0.5898047 |
| Fifty Two Week Change Percent | -97.56863 |
| Fifty Two Week High | 54.0 |
| Fifty Two Week High Change | -52.83 |
| Fifty Two Week High Change Percent | -0.97833335 |
| Fifty Two Week Low | 1.1535 |
| Fifty Two Week Low Change | 0.016499996 |
| Fifty Two Week Low Change Percent | 0.014304289 |
| Fifty Two Week Range | 1.1535 - 54.0 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,422,541,800,000 |
| Float Shares | 586,436 |
| Forward Eps | -8.28 |
| Forward P E | -0.14130434 |
| Free Cashflow | -509,881 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 11 |
| Fullday Change | -0.08000004 |
| Fullday Change Percent | -6.451616 |
| Fullday Price | 1.17 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.0 |
| Gross Profits | -1,634,614 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.10435 |
| Held Percent Institutions | 0.09674 |
| Implied Shares Outstanding | 2,385,282 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,773,014,400 |
| Last Split Factor | 1:12 |
| Long Business Summary | Decoy Therapeutics Inc. operates as a pre-clinical stage biotechnology company. It focuses on advancing the peptide conjugate therapeutics through its Immediate Peptide/PPMO/P-PROTAC Alpha-helical Conjugate Technology (IMP3ACT) platform that leverages peptide coiled-coils chemistry and physics to design a-helical peptides through computational and ML tools. The company's IMP3ACT platform leverages machine learning and artificial intelligence tools alongside synthesis techniques to engineer, enhance, and manufacture peptide conjugates targeting various unmet medical needs. It focuses on building a portfolio of peptide conjugate therapeutics focusing on infectious diseases and oncology. The company was formerly known as Salarius Pharmaceuticals, Inc. and change its name to Decoy Therapeutics Inc. in January 2026. Decoy Therapeutics Inc. is based in Houston, Texas. |
| Long Name | Decoy Therapeutics Inc. |
| Market | us_market |
| Market Cap | 2,790,779 |
| Market State | PRE |
| Max Age | 86,400 |
| Message Board Id | finmb_330031056 |
| Most Recent Quarter | 1,782,777,600 |
| Name Change Date | 2,026-10-15 |
| Net Income To Common | -14,449,550 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 2,031,073 |
| Number Of Analyst Opinions | 1 |
| Open | 1.27 |
| Operating Cashflow | -8,324,525 |
| Operating Margins | -10.558371 |
| Payout Ratio | 0.0 |
| Phone | 713 913 5608 |
| Prev Name | Salarius Pharmaceuticals, Inc. |
| Previous Close | 1.24 |
| Price Eps Current Year | -0.13058035 |
| Price Hint | 4 |
| Price To Book | 0.14405319 |
| Price To Sales Trailing12 Months | 12.260208 |
| Profit Margins | 0.0 |
| Quick Ratio | 1.771 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.0 |
| Region | US |
| Regular Market Change | -0.07000005 |
| Regular Market Change Percent | -5.6451654 |
| Regular Market Day High | 1.27 |
| Regular Market Day Low | 1.1535 |
| Regular Market Day Range | 1.1535 - 1.27 |
| Regular Market Open | 1.27 |
| Regular Market Previous Close | 1.24 |
| Regular Market Price | 1.17 |
| Regular Market Time | 1,792,008,002 |
| Regular Market Volume | 88,905 |
| Return On Assets | -0.73346 |
| Return On Equity | -8.27774 |
| Revenue Per Share | 0.636 |
| Sand P52 Week Change | 0.1570785 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 2,385,282 |
| Shares Percent Shares Out | 0.22950001 |
| Shares Short | 150,336 |
| Shares Short Previous Month Date | 1,788,134,400 |
| Shares Short Prior Month | 13,152 |
| Short Name | Decoy Therapeutics Inc. |
| Short Percent Of Float | 0.2305 |
| Short Ratio | 0.02 |
| Source Interval | 15 |
| State | TX |
| Symbol | DCOY |
| Target High Price | 3.0 |
| Target Low Price | 3.0 |
| Target Mean Price | 3.0 |
| Target Median Price | 3.0 |
| Total Cash | 8,289,108 |
| Total Cash Per Share | 12.652 |
| Total Debt | 0 |
| Total Revenue | 227,629 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | 11.55 |
| Trailing P E | 0.1012987 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 6.030485 |
| Two Hundred Day Average Change | -4.860485 |
| Two Hundred Day Average Change Percent | -0.80598575 |
| Type Disp | Equity |
| Volume | 88,905 |
| Website | https://decoytx.com |
| Zip | 77,021 |